Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.57 |
| ▸ | CALCR | P30988 | 6/20 | 0.57 |
| ▸ | APLNR | P35414 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.55 |
| ▸ | F2 | P00734 | 4/20 | 0.54 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.51 |
| ▸ | RAMP3 | O60896 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416061 | 0.89 | MAPK8 (0.63) | MAPK8MAPK9MAPK10CALCRAPLNR | |
| SCHEMBL38662088 | 0.87 | APLNR (0.63) | MAPK8MAPK9MAPK10CALCRAPLNR | |
| SCHEMBL30455558 | 0.87 | APLNR (0.62) | CALCRAPLNRKEAP1MC4RRAMP3 | |
| SCHEMBL29678024 | 0.86 | OPRM1 (0.58) | CALCRAPLNRMC4R | |
| SCHEMBL30272472 | 0.86 | APLNR (0.57) | MAPK8MAPK9MAPK10CALCRAPLNR | |
| SCHEMBL31691514 | 0.85 | APLNR (0.62) | MAPK8MAPK9MAPK10CALCRAPLNR | |
| SCHEMBL31182889 | 0.85 | MAPK8 (0.68) | MAPK8MAPK9MAPK10CALCRAPLNR | |
| SCHEMBL29822539 | 0.85 | F2 (0.62) | MAPK8MAPK9MAPK10CALCRAPLNR | |
| SCHEMBL31558595 | 0.85 | F2 (0.58) | MAPK8MAPK9MAPK10CALCRAPLNR | |
| SCHEMBL31558553 | 0.85 | F2 (0.58) | MAPK8MAPK9MAPK10CALCRAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230193291-A1 | METHOD FOR PRODUCING BLOCKPOYMERS BY MEANS OF LINKING BLOCKS BY A TRANSPEPTIDASE, AND BLOCK POLYMERS OBTAINED BY TRANSPEPTIDASE LINKING | FRAUNHOFER GES FORSCHUNG (DE) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230193291-A1 | METHOD FOR PRODUCING BLOCKPOYMERS BY MEANS OF LINKING BLOCKS BY A TRANSPEPTIDASE, AND BLOCK POLYMERS OBTAINED BY TRANSPEPTIDASE LINKING | RNPEP, DNPEP, ENPEP | MAPK8 3571/4885MAPK9 4028/4885MAPK10 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.